% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • neshua10 neshua10 Nov 8, 2013 8:57 PM Flag

    Positive Seeking Alpha article today not because it was good but because it was accuirate, moroever, the

    and when I think about it, was the best CC in the company's history, The fact is that CDX-1127 shows
    practically zero toxicity in combination with diverse typical treatment protocols for different cancers
    is beyond excellent, And the preclinical and now phase I results in shrinking tumors and PFS increase
    of nearly 470% above the average (3 to 14 months) is beyond impressive, astounding, spectacular! Granted it is a small inview at present but there is every reason for results here to remain consistent in larger targeted phase II trials, especially as the population were exposed to everything. And with the latter in mind look again at the PFS 3 to 14 months, wow and with an individual who is 84 yrs old. Does the market realize the Full potential implication, the answer is rhetorical not quite, not yet, Does the the top two sitting for Q&A in the global immuntherapeutic rearch arena do, a simple and loud YEs. Listen to their opening remarks on the review of the data on 1127. They could not find another example to compare past or present at the non-toxicity (again across, in combination with many different treatment protocols, even at this very early stage) and the novel impressive evincing effect of potentially being an entirely new Breakthrough development in the immunotherapeutic treatment of cancers. We have here a very probable Rosseta stone!

    "Overall, three patients demonstrated significant tumor shrinkage and eight patients with stable disease or better (PFS range of 3.0 to 14+ months)."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
3.34-0.10(-2.91%)Oct 21 4:00 PMEDT